Neogen Past Earnings Performance

Past criteria checks 0/6

Neogen's earnings have been declining at an average annual rate of -72.8%, while the Medical Equipment industry saw earnings growing at 12.9% annually. Revenues have been growing at an average rate of 20.2% per year.

Key information

-72.8%

Earnings growth rate

-65.6%

EPS growth rate

Medical Equipment Industry Growth8.9%
Revenue growth rate20.2%
Return on equity-17.8%
Net Margin-52.1%
Last Earnings Update30 Nov 2024

Recent past performance updates

Recent updates

Neogen: Food Safety Play Is Far From A Safe Pay

Jan 14

Risks To Shareholder Returns Are Elevated At These Prices For Neogen Corporation (NASDAQ:NEOG)

Dec 03
Risks To Shareholder Returns Are Elevated At These Prices For Neogen Corporation (NASDAQ:NEOG)

Does Neogen (NASDAQ:NEOG) Have A Healthy Balance Sheet?

Nov 07
Does Neogen (NASDAQ:NEOG) Have A Healthy Balance Sheet?

Neogen Stock: Expect Volatility To Continue Amid Weak Growth

Oct 11

Risks To Shareholder Returns Are Elevated At These Prices For Neogen Corporation (NASDAQ:NEOG)

Aug 28
Risks To Shareholder Returns Are Elevated At These Prices For Neogen Corporation (NASDAQ:NEOG)

We Think Neogen (NASDAQ:NEOG) Is Taking Some Risk With Its Debt

Jul 31
We Think Neogen (NASDAQ:NEOG) Is Taking Some Risk With Its Debt

Neogen Corporation: Challenges Remain

Jun 26

There's Reason For Concern Over Neogen Corporation's (NASDAQ:NEOG) Price

May 21
There's Reason For Concern Over Neogen Corporation's (NASDAQ:NEOG) Price

Battered By M&A Integration Issues, Neogen Has To Rebuild Investor Trust

Apr 15

Neogen Corporation Just Reported A Surprise Loss: Here's What Analysts Think Will Happen Next

Apr 12
Neogen Corporation Just Reported A Surprise Loss: Here's What Analysts Think Will Happen Next

Neogen (NASDAQ:NEOG) Takes On Some Risk With Its Use Of Debt

Mar 29
Neogen (NASDAQ:NEOG) Takes On Some Risk With Its Use Of Debt

Neogen: All About Execution From Here On

Mar 26

Statutory Profit Doesn't Reflect How Good Neogen's (NASDAQ:NEOG) Earnings Are

Jan 17
Statutory Profit Doesn't Reflect How Good Neogen's (NASDAQ:NEOG) Earnings Are

Neogen Corporation Just Missed Earnings With A Surprise Loss - Here Are Analysts Latest Forecasts

Jan 12
Neogen Corporation Just Missed Earnings With A Surprise Loss - Here Are Analysts Latest Forecasts

Neogen Corporation (NASDAQ:NEOG) Investors Are Less Pessimistic Than Expected

Jan 09
Neogen Corporation (NASDAQ:NEOG) Investors Are Less Pessimistic Than Expected

Here's Why Neogen (NASDAQ:NEOG) Can Manage Its Debt Responsibly

Dec 06
Here's Why Neogen (NASDAQ:NEOG) Can Manage Its Debt Responsibly

Neogen (NASDAQ:NEOG) Has A Somewhat Strained Balance Sheet

Jul 12
Neogen (NASDAQ:NEOG) Has A Somewhat Strained Balance Sheet

Is There An Opportunity With Neogen Corporation's (NASDAQ:NEOG) 46% Undervaluation?

Jun 20
Is There An Opportunity With Neogen Corporation's (NASDAQ:NEOG) 46% Undervaluation?

Neogen (NASDAQ:NEOG) Has A Somewhat Strained Balance Sheet

Mar 25
Neogen (NASDAQ:NEOG) Has A Somewhat Strained Balance Sheet

Neogen introduces ready-to-use disinfectant Companion RTU for veterinary use

Oct 10

Neogen GAAP EPS of $0.05, revenue of $132.35M

Sep 27

Neogen drops 9% as merger with 3M’s food safety business closes

Sep 01

Broker Revenue Forecasts For Neogen Corporation (NASDAQ:NEOG) Are Surging Higher

Aug 21
Broker Revenue Forecasts For Neogen Corporation (NASDAQ:NEOG) Are Surging Higher

Neogen: Cut In Half, Still Some Questions

Aug 12

There May Be Reason For Hope In Neogen's (NASDAQ:NEOG) Disappointing Earnings

Aug 04
There May Be Reason For Hope In Neogen's (NASDAQ:NEOG) Disappointing Earnings

Revenue & Expenses Breakdown

How Neogen makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqGS:NEOG Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Nov 24914-47638120
31 Aug 24912-2437321
31 May 24924-936722
29 Feb 24929231824
30 Nov 239191235627
31 Aug 23919-2733428
31 May 23822-2328026
28 Feb 23721-1326723
30 Nov 22631-1618520
31 Aug 225313614518
31 May 225274814217
28 Feb 225144915417
30 Nov 215035713317
31 Aug 214876212817
31 May 214686112216
28 Feb 214506112016
30 Nov 204336011415
31 Aug 204266111315
31 May 204185911415
29 Feb 204195911415
30 Nov 194176011214
31 Aug 194166011214
31 May 194146011113
28 Feb 194136210911
30 Nov 184106510911
31 Aug 184036610711
31 May 183986310511
28 Feb 183895810411
30 Nov 173825210211
31 Aug 17372469911
31 May 17358449410
28 Feb 17353419510
30 Nov 16341399310
31 Aug 16330379010
31 May 16321378710
29 Feb 16310368410
30 Nov 15301358110
31 Aug 15290347910
31 May 15283347710
28 Feb 1527232759
30 Nov 1426531759
31 Aug 1425629739
31 May 1424728718
28 Feb 1423628688

Quality Earnings: NEOG is currently unprofitable.

Growing Profit Margin: NEOG is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: NEOG is unprofitable, and losses have increased over the past 5 years at a rate of 72.8% per year.

Accelerating Growth: Unable to compare NEOG's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: NEOG is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (17.9%).


Return on Equity

High ROE: NEOG has a negative Return on Equity (-17.85%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/30 18:44
End of Day Share Price 2025/01/30 00:00
Earnings2024/11/30
Annual Earnings2024/05/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Neogen Corporation is covered by 18 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
David WestenbergCL King & Associates, Inc.
Steven CrowleyCraig-Hallum Capital Group LLC
Paul KnightCredit Agricole Securities (USA) Inc.